Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Accumulated Expenses: 2012-2025

Historic Other Accumulated Expenses for Cytokinetics (CYTK) over the last 9 years, with Sep 2025 value amounting to $12.0 million.

  • Cytokinetics' Other Accumulated Expenses rose 12.63% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 12.63%. This contributed to the annual value of $9.8 million for FY2024, which is 7.06% down from last year.
  • Latest data reveals that Cytokinetics reported Other Accumulated Expenses of $12.0 million as of Q3 2025, which was up 25.46% from $9.6 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Other Accumulated Expenses ranged from a high of $14.8 million in Q1 2024 and a low of $2.4 million during Q1 2021.
  • Its 3-year average for Other Accumulated Expenses is $10.6 million, with a median of $10.6 million in 2023.
  • Per our database at Business Quant, Cytokinetics' Other Accumulated Expenses skyrocketed by 296.58% in 2021 and then slumped by 42.47% in 2025.
  • Over the past 5 years, Cytokinetics' Other Accumulated Expenses (Quarterly) stood at $5.6 million in 2021, then rose by 11.78% to $6.2 million in 2022, then spiked by 69.65% to $10.6 million in 2023, then fell by 7.06% to $9.8 million in 2024, then climbed by 12.63% to $12.0 million in 2025.
  • Its Other Accumulated Expenses was $12.0 million in Q3 2025, compared to $9.6 million in Q2 2025 and $8.5 million in Q1 2025.